Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Physiomics ( (GB:PYC) ) is now available.
Physiomics plc announced that it is performing in line with market expectations for the fiscal year ending June 2025, with anticipated income reflecting signed contracts and a slight reduction in expected losses due to improved operational efficiencies and maintained day rates with key customers. The company is in discussions for additional contracts but cannot guarantee they will be finalized within the current fiscal year. Interim results for the six months ending December 2024 are expected to be reported in early March 2025.
More about Physiomics
Physiomics plc is a prominent company in the mathematical modelling, data science, and biostatistics industry, specializing in supporting the development of new therapeutics and personalized medicine solutions. The company leverages its expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics, combined with deep biology knowledge, to assist biotech and pharma companies in optimizing their drug development processes. Physiomics has played a role in over 100 commercial projects, working with notable clients like Merck KGaA, Astellas, and Bicycle Therapeutics, among others.
YTD Price Performance: 46.67%
Average Trading Volume: 4,012,991
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £2.08M
See more data about PYC stock on TipRanks’ Stock Analysis page.
